Efficacy at 52 weeks of daily clinical use of iguratimod in patients with rheumatoid arthritis

Modern Rheumatology

Volumn 25, Issue 4, 2015, Pages 534-539

  Okamura, Koichi ^a   Yonemoto, Yukio ^a   Suto, Takahito ^a   Okura, Chisa ^a   Takagishi, Kenji ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Disease modifying antirheumatic drugs; Iguratimod; Matrix metalloproteinase 3; Methotrexate; Rheumatoid arthritis

Indexed keywords

ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; IGURATIMOD; METHOTREXATE; STROMELYSIN; WARFARIN; CHROMONE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL TRIAL; DAS28; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; MALE; NONHUMAN; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; SURVIVAL RATE; ARTHRITIS, RHEUMATOID; BLOOD; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CHROMONES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84934893887     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2014.998361     Document Type: Article

References (34)

1. O’Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369(4):307–18.
2. Wailoo A, Hernández MA, Scott IC, Ibrahim F, Scott DL. Cost-eff ectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis. Rheumatology (Oxford). 2014;53(10): 1773–7.
3. van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012;379(9827):1712–20.
4. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations forthe management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964–75.
5. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014; 73(3): 492–509.
6. Inokuma S. Lefl unomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic drug-induced lung injury. Expert Opin Drug Saf. 2011;10(4):603–11.
7. Sato T, Inokuma S, Sagawa A, Matsuda T, Takemura T, Otsuka T, et al. Factors associated with fatal outcome of lefl unomide-induced lung injury in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48(10):1265–8.
8. Sawada T, Inokuma S, Sato T, Otsuka T, Saeki Y, Takeuchi T, et al. Lefl unomide-induced interstitial lung disease:prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48(9):1069–72.
9. Tanaka K, Makino S, Shimotori T, Aikawa Y, Inaba T, Yoshida C. Pharmacological studies of the new antiinfl ammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4’-1-benzopyran-4-o ne. 2nd communication: eff ect on the arachidonic acid cascades. Arzneimittelforschung. 1992;42(7):945–50.
10. Tanaka K, Shimotori T, Makino S, Aikawa Y, Inaba T, Yoshida C, Takano S. Pharmacological studies of the new antiinfl ammatory agent -formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one. 1st communication: anti-infl ammatory, analgesic and other related proper ties. Arzneimittelforschung. 1992; 42(7): 935–44.
11. Tanaka K, Shimotori T, Makino S, Eguchi M, Asaoka K, Kitamura R, Yoshida C. Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinfl ammatory agent. 3rd communication: the involvement of bradykinin in its analgesic actions. J Pharmacobiodyn. 1992;15(11):641–7.
12. Tanaka K, Aikawa Y, Kawasaki H, Asaoka K, Inaba T, Yoshida C. Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinfl ammatory agent. 4th communication: inhibitory eff ect on the production of interleukin-1 and interleukin-6. J Pharmacobiodyn. 1992; 15(11): 649–55.
13. Kawakami A, Tsuboi M, Urayama S, Matsuoka N, Yamasaki S, Hida A, et al. Inhibitory eff ect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J Lab Clin Med. 2012;133(6):566–74.
14. Du F, Lü LJ, Fu Q, Dai M, Teng JL, Fan W, et al. T-614, a novel immunomodulator, attenuates joint infl ammation and articular damage in collagen-induced arthritis. Arthritis Res Ther. 2008;10(6):R136.
15. Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, Kawahito Y, et al. Inhibitory eff ect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J Rheumatol. 2001;28(12):2591–6.
16. Luo Q, Sun Y, Liu W, Qian C, Jin B, Tao F, et al. A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. J Immunol. 2013;191(10):4969–78.
17. Tanaka K, Yamamoto T, Aikawa Y, Kizawa K, Muramoto K, Matsuno H, et al. Inhibitory eff ects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology (Oxford). 2003;42(11):1365–71.
18. Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K, Tanaka K. An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS-and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflamm Res. 2002;51(4):188–94.
19. Tanaka K, Shimotori T, Taniguchi Y, Eguchi M, A be C. Pharmacological studies of T-614, a novel antiinfl ammaory agent. Eff ect on type II collagen-induced arthritis in DBA/1J mice and spontaneous arthritis in MRL/l mice. Int J Immunother. 1993;9:69–78.
20. Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, et al. Effi cacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol. 2007;17(1):1–9.
21. Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, et al. Safety and effi cacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: An open-label extension of a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2014;24(3):410–8.
22. Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T, et al. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2013;23(3):430–9.
23. Lü LJ, Teng JL, Bao CD, Han XH, Sun LY, Xu JH, et al. Safety and effi cacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial. Chin Med J (Engl). 2008;121(7):615–9.
24. Lu LJ, Bao CD, Dai M, Teng JL, Fan W, Du F, et al. Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis Rheum. 2008;61(7):979–87.
25. Li J, Mao H, Liang Y, Lu Y, Chen S, Yang N, Shi G. Effi cacy and safety of iguratimod for the treatment of rheumatoid arthritis. Clin Dev Immunol. 2013;2013:310628.
26. Mucke HA. Iguratimod: a new disease-modifying antirheumatic drug. Drugs Today (Barc). 2012;48(9):577–86.
27. Okamura K, Yonemoto Y, Okura C, Kobayashi T, Takagishi T. Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis. Mod Rheumatol. 2014;28:1–6.
28. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classifi cation of rheumatoid arthritis. Arthritis Rheum. 1998;31(3):315–24.
29. Mallinckrodt CH, Sanger TM, Dubé S, DeBrota DJ, Molenberghs G, Carroll RJ, et al. Assessing and interpreting treatment eff ects in longitudinal clinical trials with missing data. Biol Psychiatry. 2003;53(8):754–60.
30. Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis. 2005;64(9):1274–9.
31. Aletaha D, Stamm T, Kapral T, Eberl G, Grisar J, Machold KP, et al. Survival and eff ectiveness of lefl unomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis. 2003;62(10):944–51.
32. van Roon EN, Hoekstra M, Tobi H, Jansen TL, Ber nelot Moens HJ, Brouwers JR, van de Laar MA. Lefl unomide in the treatment of rheumatoid arthritis. An analysis of predictors for treatment continuation. Br J Clin Pharmacol. 2005;60(3):319–25.
33. Du F, Lü LJ, Teng JL, Shen N, Ye P, Bao CD. T-614 alters the production of matrix metalloproteinases (MMP-1 and MMP-3) and inhibits the migratory expansion of rheumatoid synovial fi broblasts, in vitro. Int Immunopharmacol. 2012;13(1):54–60.
34. Tanaka K, Kawasaki H, Kurata K, Aikawa Y, Tsukamoto Y, Inaba T. T-614 a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol. 1995;67(4):305–14.